Choosing between TrimRX and Hims for GLP-1 weight loss medications in 2026 requires balancing cost-efficiency with long-term brand stability. While Hims has transitioned toward a primary partnership with Novo Nordisk for FDA-approved supply, TrimRX remains a competitive option for high-volume cash-pay patients seeking lower per-month pricing through multi-month commitments.
The primary difference between the two platforms lies in their medication sourcing and clinical structure. Hims operates as a publicly traded healthcare giant with a broad ecosystem, while TrimRX (operated by MetaFit Pharma Solutions LLC) focuses exclusively on compounded semaglutide and tirzepatide with an aggressive, volume-based pricing model.
Trim RX vs Hims: At-a-Glance Comparison
| Feature | Trim RX (2026) | Hims/Hers (2026) |
|---|---|---|
| Overall Score | 3.0/5.0 (Mixed Signals) | 4.0/5.0 (Strong Choice) |
| Tier Status | Mixed Signals | Strong Choice |
| Semaglutide Cost | $174 – $349 /mo | $298 /mo (Average) |
| Tirzepatide Cost | $283 – $449 /mo | N/A (Limited availability) |
| Medication Type | Compounded only | Brand-name & Compounded |
| Onboarding | 37-screen async intake | App-based, 24/7 care |
| Geographic Access | Most US states | Nationwide (varies by drug) |
| Lab Testing | Not included | Not included |
Key Differences Between Trim RX and Hims
Before diving into the detailed cost breakdown, it is essential to understand the structural differences that define these two providers.
- Medication Sourcing Strategy: Following the landmark March 2026 partnership between Hims and Novo Nordisk, Hims has pivoted toward providing FDA-approved Wegovy and Ozempic as its primary offering. TrimRX, conversely, relies entirely on compounded versions of semaglutide and tirzepatide sourced from partner pharmacies.
- Commitment vs. Flexibility: TrimRX achieves its lowest prices ($174/month for semaglutide) only when patients pay for 12 months upfront. Hims uses a subscription-based membership model ($39 first month, $149/month ongoing) plus the cost of the medication, allowing for more monthly flexibility but often a higher total cost over a year.
- Clinical Experience: Hims offers a robust mobile app with 24/7 access to care teams. TrimRX utilizes a massive 37-screen asynchronous intake form that can be completed without a live video call, which favors speed over deep clinical interaction.
- Corporate Transparency: Hims is a publicly traded company (NYSE: HIMS) with high regulatory visibility. TrimRX is a private entity (MetaFit Pharma Solutions LLC) that has faced scrutiny regarding founder transparency and inconsistent public records.
Pricing Comparison: The True Cost of GLP-1 Therapy
When evaluating TrimRX cost against Hims, patients must look past the "teaser" prices and calculate the annual out-of-pocket expenditure.
Trim RX 2026 Pricing Structure
TrimRX incentivizes long-term loyalty through steep discounts on multi-month bundles. As of July 2026, their pricing for compounded semaglutide is:
- 1 Month: $349
- 3 Months: $266/mo ($799 upfront)
- 6 Months: $216/mo ($1,299 upfront)
- 12 Months: $174/mo ($2,090 upfront)
For compounded tirzepatide (the active ingredient in Mounjaro and Zepbound), the costs are higher:
- 1 Month: $449
- 3 Months: $366/mo ($1,099 upfront)
- 6 Months: $316/mo ($1,899 upfront)
- 12 Months: $283/mo ($3,399 upfront)
Note: TrimRX currently offers a Winter Special of $140 off the first month for new patients.
Hims 2026 Pricing Structure
The Hims model changed significantly in March 2026. Their pricing is now split into two components:
- Membership Fee: $39 for the first month, then $149/month thereafter.
- Medication Cost: Starts as low as $149/month for certain GLP-1 options.
- Total Monthly Average: ~$298/month after the initial discount period.
While Hims is more expensive on a month-to-month basis than TrimRX's 12-month plan, Hims provides access to brand-name Wegovy and Ozempic, which may be a priority for patients wary of compounded formulations.
Cost Structure Comparison: What You Actually Pay Over Time
The advertised monthly number is only part of the story. The bigger difference is how each platform collects payment. TrimRX uses steep discounts to encourage longer commitments, but those discounts require paying upfront for multi-month plans. Hims uses monthly billing, so the effective annual cost can be higher even when the entry price looks lower.
| Plan Duration | TrimRX Semaglutide | TrimRX Tirzepatide | Hims Total |
|---|---|---|---|
| 1 month | $349 | $449 | $39 first month + $149 med = $188 |
| 3 months | $768 ($256/mo) | $1,099 ($366/mo) | $447 membership + $447 med = $894 ($298/mo) |
| 6 months | $1,146 ($191/mo) | $1,899 ($316/mo) | $894 membership + $894 med = $1,788 ($298/mo) |
| 12 months | $2,088 ($174/mo) | $3,399 ($283/mo) | $1,788 membership + $1,788 med = $3,576 ($298/mo) |
Two structural details matter here. First, TrimRX requires upfront payment for multi-month plans, so the lower effective monthly rate comes with a bigger cash commitment on day one. That can make the 6-month and 12-month offers look cheaper on paper while still requiring a much larger initial outlay than a monthly membership model. For patients comparing cash flow instead of just annual totals, that distinction matters as much as the headline monthly price.
Second, Hims bills monthly, which is easier to stop or change but keeps the all-in annual spend higher for patients who stay on treatment continuously. Over a full year, the gap becomes substantial: $2,088 for TrimRX semaglutide on a 12-month prepay versus $3,576 for a Hims membership-plus-medication path at $298 per month. TrimRX tirzepatide is also lower than the Hims annual total shown here, but that comparison involves compounded tirzepatide on one side and a different medication mix on the other, so it should not be treated as a like-for-like clinical equivalent.
The sourcing model also changes the value equation. Hims provides brand-name Wegovy and Ozempic through its Novo Nordisk collaboration and also maintains some compounded availability in limited cases. TrimRX provides compounded medications only. That means the cost comparison is not just about price; it is also about whether you want branded supply with monthly flexibility or compounded supply with prepaid discounts.
There is also a practical switching cost hidden inside the numbers. If a patient starts with TrimRX on a prepaid bundle and decides after a few weeks that they want brand-name medication instead, the lower monthly rate can quickly stop looking like a bargain. With Hims, the higher ongoing monthly spend buys more flexibility because the patient is not locked into a long prepaid term.
For buyers who think they are likely to stay on one medication for the full year and are comfortable with compounded treatment, TrimRX's pricing structure can be attractive. For buyers who are uncertain, want a lighter upfront commitment, or expect they may need to change therapies, Hims' monthly structure may be easier to live with even though the total annual spend is higher.
Medication Availability and Sourcing
The 2026 landscape for GLP-1 medications is split between "Brand-Name" supply and "Compounded" alternatives.
The Hims Shift to FDA-Approved Supply
In March 2026, Hims and Novo Nordisk entered a formal partnership. This agreement followed a period of legal tension regarding Hims' promotion of compounded semaglutide. Under the new deal, Hims serves as a major digital distributor for Wegovy (including the injectable and the newer oral "Wegovy Pill") and Ozempic.
For patients, this means Hims is now a "Strong Choice" for those who want the insurance that comes with FDA-approved labels and manufacturer-backed quality control.
Trim RX and the Compounding Niche
TrimRX remains firmly in the compounding space. Trim RX holds LegitScript certification for both its pharmacy and telehealth operations (checked September 7, 2026). This certification is a critical trust signal, as it verifies that the pharmacy meets specific safety and legal standards. However, because these are compounded medications, they are not technically "FDA-approved," though they are often produced in FDA-registered facilities.
Patients choosing TrimRX typically do so because they are self-paying and want to avoid the high retail prices of brand-name Zepbound or Wegovy, which can exceed $1,000/month without insurance.
Clinical Support and Patient Flow
The "patient journey" differs wildly between these two platforms.
Trim RX: The Asynchronous Speed-Run
TrimRX is designed for efficiency. Their 37-screen intake process is entirely asynchronous. This means you answer questions, upload a photo of your ID, and wait for a provider to review your file. There is typically no live video consultation. This is ideal for busy professionals who already understand GLP-1 medications but can be overwhelming for first-time users who have questions about side effects or injection techniques.
Hims: App-Integrated Care
Hims utilizes a sophisticated mobile app that provides 24/7 access to your care team. Following their partnership with Novo Nordisk, the clinical guidelines on the Hims platform have been tightened to align with manufacturer recommendations. Patients receive regular check-ins and have access to a library of educational content.
Program Support Model: What Each Provider Includes
Support looks very different once you move past the headline medication offer. TrimRX centers its program around an asynchronous intake and email-based follow-up. Hims wraps medication access inside a broader app-based membership that includes messaging, tracking, and ongoing support tools, but still does not include some services first-time GLP-1 users often expect.
| Feature | TrimRX | Hims |
|---|---|---|
| Provider consultation | Yes (async, 37-screen intake) | Yes (async + app-based) |
| Lab testing | Not included | Not included |
| Dietitian access | Not included (marketed but not verified) | Not included |
| 24/7 app access | No (email-based support) | Yes (mobile app, 24/7 messaging) |
| Novo Nordisk partnership | No | Yes (March 2026) |
| Medication options | Compounded semaglutide + tirzepatide | Brand-name Wegovy/Ozempic + compounded |
| HSA/FSA accepted | Yes | Yes |
| BBB rating | F, not accredited (read 14 Oct 2026) | Not checked |
| Trustpilot | 3.3/5 (727 reviews) | 3.0/5 (8,000+ reviews) |
The practical takeaway is straightforward. Neither provider includes lab testing, and neither clearly includes dietitian care as a core benefit. That means patients who want baseline metabolic data, kidney or liver monitoring, or structured nutrition counseling may still need outside care regardless of which platform they choose.
Hims offers the stronger digital support environment because its membership is built around a mobile app with continuous access and messaging. That can matter for side-effect troubleshooting, refill communication, and routine questions between check-ins. For a patient who wants a familiar subscription-style consumer health experience, Hims feels more built out.
TrimRX is leaner and more transactional, which may appeal to experienced cash-pay buyers but may feel sparse for patients who want more day-to-day guidance. The support model is more dependent on asynchronous review and email-based contact, so the overall experience may suit a patient who already knows what they want and is less reliant on app-based hand-holding.
This section also helps explain why the two providers land in different methodology tiers. TrimRX sits in the "Mixed Signals" category, while Hims/Hers is a "Strong Choice" under the GLP-1 Reviews methodology. The distinction is not just about medication access. It is also about the depth of infrastructure around the patient after signup.
Eligibility and Disqualifying Criteria
The intake flow matters because it is one of the clearest windows into how a provider screens for safety before prescribing a GLP-1 medication. Both providers use asynchronous clinical review, but the structure and depth of screening are different.
TrimRX intake screening
TrimRX uses a 37-screen flow spread across 5 clinical stages. The intake screens for family history of medullary thyroid carcinoma (MTC) and MEN-2, along with substance and opioid use within a 3-month window, suicidality, cancer history, end-stage kidney or liver disease, and severe gastrointestinal conditions. Those are meaningful safety checks and help explain why TrimRX still earns credit for clinical rigor despite its broader transparency issues.
At the same time, the intake has visible gaps. There is no PHQ-2 depression screen, no eating-disorder screen, no allergy screen, and no ID photo verification step in the flow described here. The gender field is also limited to Male and Female only, which makes the intake feel narrower and less modern than some peers.
Hims intake screening
Hims uses a 38-screen flow across 12 stages. The most notable difference is the eating-disorder safety flow: Hims includes 3 dedicated screens plus a mandatory acknowledgment before the patient can continue. The intake also includes a direct self-harm question, a black-box family-history screen covering MTC, MEN2, pancreatitis, gastroparesis, and Long QT, and a family-history question about sudden cardiac death under age 40.
Hims also includes an AUDIT-C-style alcohol screen and applies a 130/80 blood pressure threshold inside the intake logic. Those are more structured risk filters than what many GLP-1 telehealth programs show publicly. However, Hims still does not include a PHQ-2 depression screener, and the lifestyle history remains fairly light, with only a single 5-point activity scale rather than deeper diet-history questions.
For first-time GLP-1 users, the difference is less about the number of screens and more about which risks are actually addressed. Hims appears more deliberate around behavioral-health and cardiac-risk flags. TrimRX covers several major contraindications but leaves more holes in psychosocial and allergy screening.
Another way to think about this is that TrimRX's screen is broad enough to catch many obvious GLP-1 contraindications, but Hims is more explicit in how it handles edge cases that can matter in telehealth prescribing. The dedicated eating-disorder flow is especially notable because rapid weight-loss treatment can be inappropriate for some patients even if they technically meet a BMI threshold.
The blood pressure threshold on Hims also gives patients a clearer sense of where the platform may pause or redirect them for additional evaluation. TrimRX asks about important history, but the structure disclosed in the review is less explicit about threshold-based disqualification logic. That does not mean the clinical review is weak; it means the patient-facing screening flow is less transparent about how those answers shape eligibility.
Both providers also leave some unanswered questions because neither flow described here includes a true depression screener such as PHQ-2. For a category where mood symptoms, self-image, eating behavior, and discontinuation pressure can intersect, that omission is worth noting. It does not automatically disqualify a provider, but it is part of the context patients should understand before assuming that an online GLP-1 intake equals a full obesity-medicine workup.
Trust, Reputation, and Legitimacy
We evaluate every provider using a weighted scoring methodology that includes authenticity, clinical quality, and reputation.
Is Trim RX Legit?
TrimRX holds a 3.0/5.0 "Mixed Signals" rating. Some patients have reported difficulty with the multi-month upfront billing, particularly when attempting to secure refunds. You can read our full investigation into whether TrimRX is legit for more details on these findings.
Hims' Reputation
Hims earns a 4.0/5.0 "Strong Choice" rating. As a public company, they have a high level of accountability. Their large user base (8,000+ Trustpilot reviews) provides a level of social proof that TrimRX currently lacks. However, their Trustpilot score (3.0/5.0) is actually slightly lower than TrimRX's (3.3/5.0), largely due to customer service complaints regarding subscription cancellations: a common issue for large telehealth platforms.
What Happens If You Need to Switch or Stop
Stopping treatment is where the billing model becomes more important than the headline monthly price.
TrimRX cancellation and switching terms
TrimRX's multi-month upfront billing makes switching difficult. If you prepay for 6 months and decide to move to a different provider after month 2, you generally forfeit the remaining 4 months. Cancellation requires emailing support, and multi-month refunds are generally not provided. That does not matter as much if you already know you want compounded treatment for the full term, but it can become expensive if side effects, medication preference, or provider confidence changes mid-course.
Hims cancellation and switching terms
Hims uses a monthly membership model, so patients can generally cancel anytime through the app or support channels without a long-term commitment. That structure is simpler for patients who are still figuring out whether GLP-1 treatment is a fit. It also creates a practical advantage for switching medication type. If a patient wants to move from compounded medication to a brand-name option, Hims can handle that within the same platform because of its broader formulary and Novo Nordisk-linked branded access. With TrimRX, a patient who wants to leave compounded treatment usually needs to start over with a different provider.
The result is a clear tradeoff. TrimRX can lower the effective monthly cost if you are comfortable committing upfront. Hims makes it easier to change course when your clinical or financial situation changes.
This is one of the most important real-world differences between the two programs because many patients do not stay on their first GLP-1 path unchanged for a full year. Some need a dosage adjustment. Some experience side effects that make them prefer a different medication. Others begin with compounded treatment to control cost and later decide they want brand-name supply for consistency or peace of mind.
Under that kind of real-world use, the cancellation mechanics matter almost as much as the starting price. A patient who values flexibility, wants a simpler off-ramp, or expects they may need to transition therapies is likely to view Hims' monthly structure as a meaningful operational advantage. A patient who already knows they want to stay with compounded treatment and is optimizing aggressively for lower monthly cost may still be comfortable accepting TrimRX's switching friction.
Corporate Transparency Comparison
Corporate transparency is one of the sharpest differences between these providers, and it helps explain why their published tier labels are not the same.
TrimRX corporate disclosure
TrimRX operates as MetaFit Pharma Solutions LLC, a private entity based in San Diego. The company does not clearly disclose its founding year. There is also a founder discrepancy in public-facing materials: the website has listed Emily Parker and Jake Miller, while BBB’s profile lists Gibran Suffy and Sergio Aguilera as qualifying partners and Jake Miller as co-founder (read 14 October 2026). Pharmacy partners are not named publicly in the same way many larger telehealth platforms disclose them. None of this proves misconduct on its own, but it does reduce the level of external visibility available to patients doing due diligence.
Hims corporate disclosure
Hims is publicly traded on the NYSE under HIMS and was founded in 2017. Its Novo Nordisk relationship has been publicly announced, its pharmacy relationships are disclosed more clearly, and the business files quarterly SEC reports that investors and patients can review. It also has more than 8,000 Trustpilot reviews, which gives buyers a much larger body of public feedback to evaluate.
For cautious first-time buyers, that transparency gap matters. It does not automatically make the lower-cost option unusable, but it does change how much independent verification a patient can do before paying.
It also affects how disputes, policy changes, and supply shifts are communicated. With Hims, investors, regulators, and customers can monitor formal disclosures through earnings materials, SEC filings, and official press releases. With TrimRX, patients rely more heavily on website claims, review patterns, and third-party business profiles because the company does not offer the same volume of standardized public reporting.
That does not mean every public company is automatically easier to deal with or that every private company is automatically suspect. It means the verification burden is different. A patient considering Hims can check a larger paper trail. A patient considering TrimRX has to be more comfortable with a narrower set of public records and some unresolved inconsistencies around corporate identity and founder disclosure.
In practice, this section ties closely to the methodology tiers already published on GLP-1 Reviews. Hims' "Strong Choice" label reflects a stronger accountability framework around the business itself, while TrimRX's "Mixed Signals" label reflects the fact that meaningful positives in pricing and intake structure coexist with real transparency gaps that patients should weigh carefully.
Best For: Which Should You Choose?
Best for Cash-Pay Value: Trim RX
If you are paying out-of-pocket and are willing to commit to a 6-month or 12-month program, TrimRX is significantly cheaper. The $174/month price point for semaglutide is one of the lowest in the industry for 2026.
Best for Brand-Name Seekers: Hims
If you prefer FDA-approved Wegovy or Ozempic and want the peace of mind of a direct manufacturer partnership, Hims is the superior choice. Their transition away from compounded drugs makes them a more stable bet for those concerned about compounding regulations.
Best for Fast Onboarding: Trim RX
If you want to complete your intake in 15 minutes without scheduling a call, TrimRX’s 37-screen async flow is built for you.
Best for Ongoing Support: Hims
If you want a dedicated app, 24/7 care team access, and a broader ecosystem of health products, Hims' "Strong Choice" status is well-earned.
FAQ: Trim RX vs Hims GLP-1 Comparisons
How much does Trim RX cost compared to Hims?
Trim RX costs between $174 and $349 per month for semaglutide, depending on your upfront commitment. Hims costs approximately $298 per month (averaging membership fees and medication costs) after the first-month discount. Trim RX is cheaper for long-term upfront buyers, while Hims offers more monthly flexibility.
Is Trim RX legit or a scam?
However, it receives a "Mixed Signals" rating due to its multi-month billing practices and less transparent corporate history. For a deeper look, see our report on is TrimRX legit.
Does Hims offer brand-name Wegovy?
Yes. As of March 2026, Hims has a partnership with Novo Nordisk to provide FDA-approved Wegovy (injections and pills) and Ozempic. They have largely moved away from mass-promoting compounded semaglutide.
Do either Trim RX or Hims take insurance?
Neither Trim RX nor Hims typically bill insurance directly for their weight loss programs. They are considered "cash-pay" platforms. However, both generally accept HSA (Health Savings Account) and FSA (Flexible Spending Account) payments for clinical fees and medications.
What happens if I want to cancel my Trim RX subscription?
Canceling a Trim RX subscription can be complex if you have paid for a multi-month bundle upfront. Refunds are generally not provided for medication that has already been shipped or for the remaining months of a pre-paid term. Always review the refund policy on the Trim RX website before paying for a 6-month or 12-month plan.
Which provider is easier to cancel?
Hims is easier to cancel because it uses a monthly membership model and in-app or support-based cancellation flow rather than requiring a large prepaid commitment. TrimRX can be harder to exit once you have paid for a multi-month bundle because unused months are generally forfeited rather than refunded.
Can I switch from compounded to brand-name with these providers?
Hims is the easier platform for switching from compounded to brand-name medication because it offers both branded and compounded GLP-1 pathways within the same ecosystem. With TrimRX, patients using compounded medication would typically need to start fresh with a new provider if they decide they want brand-name Wegovy or Ozempic instead.
These two FAQ points matter because they capture the operational difference between a low-cost prepaid compounded program and a more flexible app-based membership model. For many patients, the biggest regret is not the starting price. It is discovering too late that changing plans, stopping treatment, or moving to a different medication is more complicated than expected.
Final Verdict: The 2026 Perspective
The competition between TrimRX and Hims highlights the split in the GLP-1 market. TrimRX is a "Mixed Signals" provider that excels in raw price-per-month for those willing to take on the risk of multi-month payments and compounded medications. Hims is a "Strong Choice" provider that has leveraged its corporate scale to secure branded supply, offering a more traditional pharmaceutical experience through a modern tech interface.
The cancellation and switching policies sharpen that divide. TrimRX rewards commitment, but that same upfront billing structure can make it expensive to change course if you want to stop early or move to a brand-name option later. Hims costs more over time for many cash-pay users, but the monthly structure is easier to exit and makes it simpler to move between compounded and brand-name medication within one platform.
Most patients seeking the highest level of transparency, easier cancellation, and broader medication flexibility will find Hims to be the safer bet. Those primarily driven by cost-savings who are comfortable with compounded drugs, async care, and prepaying for longer terms will find TrimRX's bulk pricing hard to beat.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication, including GLP-1 agonists like semaglutide or tirzepatide. Be aware that GLP-1 medications carry a Boxed Warning regarding the potential risk of thyroid C-cell tumors.
Corrected 9 October 2026. We removed 4 generated images from this article, including a chart attributing supply figures to Novo Nordisk investor relations that we could not find, and mock app screens for Trim RX and Hims that were not their real apps. Generated images on this site no longer show certifications, organisations, products, prices or figures unless the specific claim has been checked.
Corrected 14 October 2026: this article said TrimRx was BBB accredited and “Not Rated”, and that BBB listed only two principals. BBB’s profile, read 14 October 2026, shows it is not accredited and rated F, and also lists Jake Miller as co-founder.
Corrected 14 October 2026: this article previously gave Better Business Bureau ratings for providers it compares, taken from our April 2026 research. We kept no record of where those ratings came from, so they have been removed.
Keep exploring our GLP-1 resources:
